147 related articles for article (PubMed ID: 35114585)
1. ISRIB plus bortezomib triggers paraptosis in breast cancer cells via enhanced translation and subsequent proteotoxic stress.
Lee DM; Seo MJ; Lee HJ; Jin HJ; Choi KS
Biochem Biophys Res Commun; 2022 Mar; 596():56-62. PubMed ID: 35114585
[TBL] [Abstract][Full Text] [Related]
2. Lercanidipine Synergistically Enhances Bortezomib Cytotoxicity in Cancer Cells via Enhanced Endoplasmic Reticulum Stress and Mitochondrial Ca
Lee AR; Seo MJ; Kim J; Lee DM; Kim IY; Yoon MJ; Hoon H; Choi KS
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817163
[TBL] [Abstract][Full Text] [Related]
3. Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis.
Lee DM; Kim IY; Seo MJ; Kwon MR; Choi KS
Exp Mol Med; 2017 Aug; 49(8):e365. PubMed ID: 28798402
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibition of thioredoxin reductase and proteasome is required for auranofin-induced paraptosis in breast cancer cells.
Seo MJ; Kim IY; Lee DM; Park YJ; Cho MY; Jin HJ; Choi KS
Cell Death Dis; 2023 Jan; 14(1):42. PubMed ID: 36658130
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress.
Kawaguchi T; Miyazawa K; Moriya S; Ohtomo T; Che XF; Naito M; Itoh M; Tomoda A
Int J Oncol; 2011 Mar; 38(3):643-54. PubMed ID: 21174067
[TBL] [Abstract][Full Text] [Related]
6. Loperamide overcomes the resistance of colon cancer cells to bortezomib by inducing CHOP-mediated paraptosis-like cell death.
Kim IY; Shim MJ; Lee DM; Lee AR; Kim MA; Yoon MJ; Kwon MR; Lee HI; Seo MJ; Choi YW; Choi KS
Biochem Pharmacol; 2019 Apr; 162():41-54. PubMed ID: 30529689
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors.
Prelowska MK; Mehlich D; Ugurlu MT; Kedzierska H; Cwiek A; Kosnik A; Kaminska K; Marusiak AA; Nowis D
Cancer Lett; 2021 Jun; 507():13-25. PubMed ID: 33713737
[TBL] [Abstract][Full Text] [Related]
8. Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress.
Wallington-Beddoe CT; Bennett MK; Vandyke K; Davies L; Zebol JR; Moretti PAB; Pitman MR; Hewett DR; Zannettino ACW; Pitson SM
Oncotarget; 2017 Jul; 8(27):43602-43616. PubMed ID: 28467788
[TBL] [Abstract][Full Text] [Related]
9. PSMD14 Targeting Triggers Paraptosis in Breast Cancer Cells by Inducing Proteasome Inhibition and Ca
Lee HJ; Lee DM; Seo MJ; Kang HC; Kwon SK; Choi KS
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269789
[TBL] [Abstract][Full Text] [Related]
10. Fine tuning of the unfolded protein response by ISRIB improves neuronal survival in a model of amyotrophic lateral sclerosis.
Bugallo R; Marlin E; Baltanás A; Toledo E; Ferrero R; Vinueza-Gavilanes R; Larrea L; Arrasate M; Aragón T
Cell Death Dis; 2020 May; 11(5):397. PubMed ID: 32457286
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells.
Kawabata S; Gills JJ; Mercado-Matos JR; Lopiccolo J; Wilson W; Hollander MC; Dennis PA
Cell Death Dis; 2012 Jul; 3(7):e353. PubMed ID: 22825471
[TBL] [Abstract][Full Text] [Related]
12. Calcium channel blocker verapamil enhances endoplasmic reticulum stress and cell death induced by proteasome inhibition in myeloma cells.
Meister S; Frey B; Lang VR; Gaipl US; Schett G; Schlötzer-Schrehardt U; Voll RE
Neoplasia; 2010 Jul; 12(7):550-61. PubMed ID: 20651984
[TBL] [Abstract][Full Text] [Related]
13. Targeting bortezomib-induced aggresome formation using vinorelbine enhances the cytotoxic effect along with ER stress loading in breast cancer cell lines.
Miyahara K; Kazama H; Kokuba H; Komatsu S; Hirota A; Takemura J; Hirasawa K; Moriya S; Abe A; Hiramoto M; Ishikawa T; Miyazawa K
Int J Oncol; 2016 Nov; 49(5):1848-1858. PubMed ID: 27601063
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological dimerization and activation of the exchange factor eIF2B antagonizes the integrated stress response.
Sidrauski C; Tsai JC; Kampmann M; Hearn BR; Vedantham P; Jaishankar P; Sokabe M; Mendez AS; Newton BW; Tang EL; Verschueren E; Johnson JR; Krogan NJ; Fraser CS; Weissman JS; Renslo AR; Walter P
Elife; 2015 Apr; 4():e07314. PubMed ID: 25875391
[TBL] [Abstract][Full Text] [Related]
15. Small molecule ISRIB suppresses the integrated stress response within a defined window of activation.
Rabouw HH; Langereis MA; Anand AA; Visser LJ; de Groot RJ; Walter P; van Kuppeveld FJM
Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2097-2102. PubMed ID: 30674674
[TBL] [Abstract][Full Text] [Related]
16. Binding of ISRIB reveals a regulatory site in the nucleotide exchange factor eIF2B.
Zyryanova AF; Weis F; Faille A; Alard AA; Crespillo-Casado A; Sekine Y; Harding HP; Allen F; Parts L; Fromont C; Fischer PM; Warren AJ; Ron D
Science; 2018 Mar; 359(6383):1533-1536. PubMed ID: 29599245
[TBL] [Abstract][Full Text] [Related]
17. Stress responses. Mutations in a translation initiation factor identify the target of a memory-enhancing compound.
Sekine Y; Zyryanova A; Crespillo-Casado A; Fischer PM; Harding HP; Ron D
Science; 2015 May; 348(6238):1027-30. PubMed ID: 25858979
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors.
Tagoug I; Jordheim LP; Herveau S; Matera EL; Huber AL; Chettab K; Manié S; Dumontet C
Clin Cancer Res; 2013 Jul; 19(13):3556-66. PubMed ID: 23674497
[TBL] [Abstract][Full Text] [Related]
19. The small molecule ISRIB reverses the effects of eIF2α phosphorylation on translation and stress granule assembly.
Sidrauski C; McGeachy AM; Ingolia NT; Walter P
Elife; 2015 Feb; 4():. PubMed ID: 25719440
[TBL] [Abstract][Full Text] [Related]
20. Pluronic block copolymers enhance the anti-myeloma activity of proteasome inhibitors.
Hu H; Petrosyan A; Osna NA; Liu T; Olou AA; Alakhova DY; Singh PK; Kabanov AV; Faber EA; Bronich TK
J Control Release; 2019 Jul; 306():149-164. PubMed ID: 31121280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
